Skip to content

Pericarditis

BASICS

  • Definition: Inflammation of the pericardium, with or without pericardial effusion.
  • Myopericarditis/perimyocarditis: Myocardial and pericardial involvement.

EPIDEMIOLOGY

  • Incidence: ~27.7/100,000 per year
  • Recurrence: ~30% after first episode within 18 months

ETIOLOGY & PATHOPHYSIOLOGY

  • Idiopathic (85–90%): Mostly viral, immune-related
  • Common viruses: Coxsackievirus, echovirus, adenovirus, EBV, CMV, hepatitis, influenza, HIV, mumps, varicella, SARS-CoV-2, parvovirus B19
  • Bacterial: M. tuberculosis, S. aureus, S. pneumoniae, anaerobes (rare in developed countries)
  • Fungal/Parasite: In immunocompromised
  • Noninfectious (15–20%):
  • Acute MI (post-infarction), Dressler syndrome, aortic dissection, uremia, malignancy, radiation, trauma, post-procedural (e.g., post-cardiac surgery), autoimmune/connective tissue disease (SLE, RA, scleroderma, sarcoidosis, IBD, Wegener)
  • Medications: dantrolene, doxorubicin, hydralazine, isoniazid, mesalamine, methysergide, penicillin, phenytoin, procainamide, rifampin
  • Vaccination (smallpox, influenza, SARS-CoV-2 mRNA)
  • Genetics: Familial Mediterranean fever, TRAPSβ€”linked to recurrent pericarditis

RISK FACTORS

  • Thoracic surgery, CKD, pneumonia, autoimmune disease, radiation (lung/breast CA), chronic infection

DIAGNOSIS

  • Criteria (need β‰₯2 of 4):
  • Pleuritic chest pain
  • Pericardial friction rub
  • New/increasing pericardial effusion (imaging)
  • ECG: widespread ST-segment elevation (diffuse), PR depression
  • Classification:
  • Incessant: symptoms >4–6 weeks but <3 months
  • Recurrent: symptoms recur after β‰₯4–6 weeks symptom-free
  • Chronic: >3 months

Myopericarditis:

  • Definite pericarditis PLUS:
  • Symptoms (dyspnea, chest pain, palpitations) and new ECG changes or LV dysfunction on imaging
  • Elevated cardiac enzymes OR abnormal MRI/gallium scan

HISTORY

  • Viral prodrome (fever, malaise, myalgias, recent URI)
  • Acute, sharp, pleuritic chest pain (radiates to trapezius; relieved by leaning forward, worse lying down)
  • Shortness of breath

PHYSICAL EXAM

  • Pericardial friction rub: coarse, high-pitched (left lower sternal border, leaning forward)
  • May be transient, variable phases
  • S3 may suggest myopericarditis

DIFFERENTIAL

  • MI/ACS, PE, aortic dissection, GERD, pneumonia

DIAGNOSTIC TESTS

  • Labs:
  • Leukocytosis
  • ↑ ESR/CRP/LDH
  • ↑ Troponin/CK (esp. myopericarditis, but not prognostic)
  • ECG:
  • Diffuse ST-elevation (concave), PR depression, low voltage or electrical alternans (large effusion/tamponade)
  • Echo:
  • Evaluate for pericardial effusion, tamponade, or myocardial disease
  • CXR:
  • Rule out other causes, cardiomegaly if large effusion
  • CT/MRI:
  • Evaluate pericardium, complications, pre-op planning
  • Other:
  • TSH, TB test, ANA, RF, HIV serology if indicated
  • Pericardiocentesis: For tamponade, suspected purulent/TB/neoplastic, effusions >20mm on echo

TREATMENT

General Measures

  • Treat underlying cause
  • Restrict physical activity (especially recurrences)

Medications

  • First Line:
  • NSAIDs: Mainstay for acute pericarditis (Ibuprofen 600 mg TID, Aspirin 1000 mg TID, Indomethacin 50 mg TID; 7–10 days, then taper)
    • Aspirin preferred post-MI
    • Indomethacin avoid in elderly/CAD
    • GI protection with PPI
    • Taper only when asymptomatic + normalized CRP/ESR (monitor 1–2 weeks)
  • Colchicine:
    • 0.5–0.6 mg BID (up to 3 months; up to 6 months if recurrent)
    • Use with NSAIDs (not alone)
    • Only agent proven to prevent recurrence (reduces by ~50%)
    • Adjust for renal/hepatic dysfunction
    • Monitor CBC, LFTs, CK, creatinine at baseline/1 month; CRP weekly
  • Pregnancy:
  • <20 wks: Aspirin preferred; NSAIDs/prednisone allowed
  • 20 wks: Prednisone only; avoid NSAIDs/aspirin/colchicine

  • Second Line:

  • Steroids: Only if NSAID/colchicine contraindicated or in CTD/TB pericarditis; avoid in uncomplicated/idiopathic acute pericarditis.
    • Low dose (0.2–0.5 mg/kg/day) until symptom/CRP normalization, then taper
    • Add calcium/vitamin D; consider bisphosphonate in high-risk
  • IL-1 antagonists:
    • Anakinra (2 mg/kg SC daily, up to 100 mg; 2–6 months)
    • Rilonacept (320 mg SC, then 160 mg weekly x12 weeks)
    • Use for refractory/recurrent cases
    • Monitor for injection site, LFTs, infections

SURGERY/PROCEDURES

  • Pericardiocentesis: Tamponade, purulent/TB/neoplastic effusions, refractory large symptomatic effusion
  • Pericardial window: Recurrent tamponade/effusion unresponsive to other tx
  • Pericardiectomy: Chronic constrictive pericarditis (NYHA III/IV) only if severe, high-mortality procedure

ADMISSION & INPATIENT CONSIDERATIONS

  • Admit for:
  • Major comorbidities
  • Refractory cases
  • Uremic/dialysis pericarditis
  • Suspected/actual tamponade
  • Immunosuppression, trauma, anticoagulation, myopericarditis, fever >38Β°C, large effusion, subacute onset, no NSAID/aspirin response

  • IV fluids: Hypotension/tamponade


ONGOING CARE

  • Follow-up: 1 week (response, CBC, CRP), then as needed based on risk/echo
  • Myopericarditis: Lower dose anti-inflammatories, 4–6 weeks exercise restriction (athletes: β‰₯3 months)
  • Echo: At 1, 6, 12 months (esp. LV dysfunction)

PROGNOSIS

  • Generally good if underlying cause treated; most cases benign/self-limited
  • Poor in purulent/TB pericarditis

COMPLICATIONS

  • Recurrence: 15–30% (often idiopathic, viral, autoimmune; usually within 1 week but can occur years later)
  • Cardiac tamponade: rare, more common in neoplastic, purulent, TB pericarditis
  • Effusive-constrictive pericarditis: 8–24% of surgical/pericardiocentesis cases (diagnosis: right atrial pressure fails to drop post-pericardiocentesis)
  • Constrictive pericarditis: rare but severe; requires pericardiectomy
  • Arrhythmias: Atrial fibrillation/flutter

ICD-10 CODES

  • I31.9 Disease of pericardium, unspecified
  • I30.9 Acute pericarditis, unspecified
  • I30.1 Infective pericarditis

CLINICAL PEARLS

  • NSAIDs + colchicine = first-line therapy; colchicine reduces recurrence by ~50%
  • Therapy targets symptom relief, recurrence prevention
  • Monitor for high-risk features (effusion, tamponade, recurrence)